103 related articles for article (PubMed ID: 18097592)
1. The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy.
Mao K; Camparo P; Badoual C; Peyromaure M; Delongchamps NB; Vieillefond A; Dinh-Xuan AT
Oncol Rep; 2008 Jan; 19(1):171-5. PubMed ID: 18097592
[TBL] [Abstract][Full Text] [Related]
2. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
[TBL] [Abstract][Full Text] [Related]
4. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate.
Li R; Younes M; Wheeler TM; Scardino P; Ohori M; Frolov A; Ayala G
Prostate; 2004 Feb; 58(2):193-9. PubMed ID: 14716745
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.
Peyromaure M; Badoual C; Camparo P; Grabar S; Goulvestre C; Fulla Y; Vieillefond A; Mao K; Dinh-Xuan AT
Oncol Rep; 2007 Jul; 18(1):145-9. PubMed ID: 17549360
[TBL] [Abstract][Full Text] [Related]
6. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy.
Moul JW; Maygarden SJ; Ware JL; Mohler JL; Maher PD; Schenkman NS; Ho CK
J Urol; 1996 Mar; 155(3):982-5. PubMed ID: 8583622
[TBL] [Abstract][Full Text] [Related]
8. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy.
Compérat E; Rouprêt M; Drouin SJ; Camparo P; Bitker MO; Houlgatte A; Cancel-Tassin G; Cussenot O
Prostate; 2010 Nov; 70(15):1622-7. PubMed ID: 20687232
[TBL] [Abstract][Full Text] [Related]
9. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer.
Talagas M; Uguen A; Garlantezec R; Fournier G; Doucet L; Gobin E; Marcorelles P; Volant A; DE Braekeleer M
Anticancer Res; 2013 May; 33(5):2065-75. PubMed ID: 23645757
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
11. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Gleave M; Fujisawa M
Urology; 2006 Sep; 68(3):609-14. PubMed ID: 16979705
[TBL] [Abstract][Full Text] [Related]
12. beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression.
Szász AM; Nyirády P; Majoros A; Szendrõi A; Szûcs M; Székely E; Tõkés AM; Romics I; Kulka J
BJU Int; 2010 Mar; 105(5):716-22. PubMed ID: 19818082
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.
Shariat SF; Svatek RS; Kabbani W; Walz J; Lotan Y; Karakiewicz PI; Roehrborn CG
BJU Int; 2008 Jan; 101(2):232-7. PubMed ID: 17868422
[TBL] [Abstract][Full Text] [Related]
14. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
[TBL] [Abstract][Full Text] [Related]
15. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
[TBL] [Abstract][Full Text] [Related]
16. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
19. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
[TBL] [Abstract][Full Text] [Related]
20. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]